Medical News

RSS

HP, mPedigree Network introduce life-saving service to fight counterfeit drugs in Africa

HP and African social enterprise mPedigree Network have introduced a potentially life-saving service that targets counterfeit pharmaceuticals by enabling people in Nigeria and Ghana to easily check the authenticity of their malaria medication.

6 Dec 2010

FIJI Water acquires JUSTIN Vineyards & Winery

FIJI® Water, the country's leading premium imported bottled water, announced today that it has acquired the award-winning JUSTIN Vineyards & Winery in Paso Robles, California. Known for its Bordeaux-style blends and single varietals, combining Old World tradition with New World techniques, JUSTIN Vineyards & Winery is a critically-acclaimed, world class premium wine brand that FIJI Water and its parent company, Roll International, are proud to add to their portfolio.

6 Dec 2010

Chemo101.com officially launched during ASH meeting

Chemo101.com, a new educational website for cancer patients, made its official launch during the American Society of Hematology meeting this past weekend in Orlando, FL. The brainchild of veteran healthcare consultant to the pharmaceutical industry, Kristin Gustafson, Chemo101 is an innovative and comprehensive new platform that provides those undergoing chemotherapy treatment with the most up-to-date resources and information they need, all in one easy to access place online.

6 Dec 2010

New research focusing on VTE presented at ASH Annual Meeting

The latest advances in the treatment of bleeding and clotting disorders will be presented today at the 52nd Annual Meeting of the American Society of Hematology, focusing on venous thrombeombolism, a potentially life-threatening disorder in which abnormal blood clots form in the veins and restrict the flow of blood. New studies examine risk-prediction models and cutting-edge treatment options for patients with VTE.

6 Dec 2010

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

6 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

Incidence of EPTS in children with TBI more than twice the rate in adults: Study

In the first study to utilize continuous EEG monitoring to define the incidence of early post traumatic seizures in children compared to published rates in adults, investigators at the University of Colorado followed pediatric patients with moderate to severe traumatic brain injury admitted to Denver Children's Hospital over a nine month period.

6 Dec 2010

First patient dosed with rFVIIIFc in A-LONG trial

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.

6 Dec 2010

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

6 Dec 2010

WebMD Health announces 2010 Year in Health

WebMD Health Corp., the leading source of health information, today announced its 2010 Year in Health, which represents the health stories, searches, questions and trends that WebMD's audience of more than 83 million monthly visitors sought from the company's websites, mobile applications and communities during the year.

6 Dec 2010

LouseBuster device proves effective

Four years after the LouseBuster prototype made headlines when research showed the chemical-free, warm-air device wiped out head lice on children, a new study reveals that a revamped, government-cleared model is highly effective.

6 Dec 2010

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Red blood cells have the very important role of carrying oxygen from the lungs to the rest of the body; therefore, disorders that affect RBCs can have a significant impact on quality of life. Sickle cell disease and malaria are two common RBC diseases that affect a significant portion of the U.S. and global populations. Sickle cell disease, a genetic blood disorder that causes deformed and dysfunctional red blood cells, affects an estimated 70,000 to 100,000 Americans, while malaria affects approximately 1,500 Americans annually and 190 to 311 million people worldwide.

6 Dec 2010

Scientists show how brain's architecture makes our view of world unique

Wellcome Trust scientists have shown for the first time that exactly how we see our environment depends on the size of the visual part of our brain.

6 Dec 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics, Inc. today announced new pixantrone end of study follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application currently under review by the European Medicines Agency.

6 Dec 2010

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Inc., a member of the Roche Group, and Biogen Idec announced today positive data from a Phase III study of Rituxan (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).

6 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

Merrion Pharmaceuticals announces oral drug delivery Feasibility and Option agreement

Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.

6 Dec 2010

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.

6 Dec 2010

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Medical News

HP, mPedigree Network introduce life-saving service to fight counterfeit drugs in Africa

FIJI Water acquires JUSTIN Vineyards & Winery

Chemo101.com officially launched during ASH meeting

New research focusing on VTE presented at ASH Annual Meeting

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Incidence of EPTS in children with TBI more than twice the rate in adults: Study

First patient dosed with rFVIIIFc in A-LONG trial

Amgen announces final study results of Nplate in adults with chronic ITP

WebMD Health announces 2010 Year in Health

LouseBuster device proves effective

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Scientists show how brain's architecture makes our view of world unique

Cell Therapeutics announces new pixantrone EOS follow up results

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Merrion Pharmaceuticals announces oral drug delivery Feasibility and Option agreement

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News